deltatrials

Crohn's disease Trials in Xiamen, China

Conditions / Crohn's disease / Xiamen, China

Clinical trials for Crohn's disease investigate a range of treatment strategies and patient populations.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID Title Status Phase
NCT06430801 A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) RECRUITING
NCT03926130 A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease COMPLETED PHASE3
NCT04232553 A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease ACTIVE_NOT_RECRUITING PHASE3
NCT06430801 A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) RECRUITING
NCT06063967 A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. ACTIVE_NOT_RECRUITING PHASE3
NCT03345849 A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies COMPLETED PHASE3
NCT03599622 An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease TERMINATED PHASE2
NCT03466411 A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease ACTIVE_NOT_RECRUITING PHASE2/PHASE3
NCT05242471 A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease ACTIVE_NOT_RECRUITING PHASE2
NCT03345823 A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 ACTIVE_NOT_RECRUITING PHASE3

Related Pages